anti-mesothelin antibody-drug conjugate BMS-986148

{
  "id": "MLC-T-ONC-010881",
  "term": "anti-mesothelin antibody-drug conjugate BMS-986148",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein and tumor-associated antigen (TAA) mesothelin and conjugated, via a valine-citrulline linker, to the cytotoxic agent tubulysin, with potential antineoplastic activity. Upon administration of anti-mesothelin ADC BMS-986148, the monoclonal antibody moiety targets and binds to mesothelin. Upon internalization, the tubulysin moiety inhibits the polymerization of tubulin into microtubules. This leads to cell cycle arrest, induces tumor cell apoptosis, and may inhibit cellular proliferation of mesothelin-expressing tumor cells. Mesothelin is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-mesothelin-antibody-drug-conjugate-bms-986148/"
}